Titre : J&J unit ends hepatitis C drug development in crowded market
link : J&J unit ends hepatitis C drug development in crowded market
J&J unit ends hepatitis C drug development in crowded market
J&J unit ends hepatitis C drug development in crowded market
(Reuters) - Janssen Sciences Ireland UC, a unit of Johnson & Johnson, said it would discontinue further development of its hepatitis C research, citing increased availability of a number of effective hepatitis C therapies.
Janssen said it would not continue the development of the investigational hepatitis C treatment regimen JNJ-4178, a combination of three direct acting antivirals.
The ongoing phase II studies with JNJ-4178 will be completed as planned, with no additional development thereafter, Janssen said in a statement on Monday.
Janssen’s hepatitis research and development efforts will continue to focus on chronic hepatitis B, the unit said.
Janssen co-developed telaprevir, a first-in-class protease inhibitor used in combination therapy for the treatment of chronic hepatitis C virus, a few years ago. In collaboration with Medivir AB , Janssen later launched the second-generation protease inhibitor OLYSIO, which is approved in several countries.
(Reuters) - Janssen Sciences Ireland UC, a unit of Johnson & Johnson, said it would discontinue further development of its hepatitis C research, citing increased availability of a number of effective hepatitis C therapies.
Janssen said it would not continue the development of the investigational hepatitis C treatment regimen JNJ-4178, a combination of three direct acting antivirals.
The ongoing phase II studies with JNJ-4178 will be completed as planned, with no additional development thereafter, Janssen said in a statement on Monday.
Janssen’s hepatitis research and development efforts will continue to focus on chronic hepatitis B, the unit said.
Janssen co-developed telaprevir, a first-in-class protease inhibitor used in combination therapy for the treatment of chronic hepatitis C virus, a few years ago. In collaboration with Medivir AB , Janssen later launched the second-generation protease inhibitor OLYSIO, which is approved in several countries.
Thus articles J&J unit ends hepatitis C drug development in crowded market
that is all articles J&J unit ends hepatitis C drug development in crowded market This time, hopefully can provide benefits to you all. Okay, see you in another article post.
You are now reading the article J&J unit ends hepatitis C drug development in crowded market the link address https://newsaninpiration.blogspot.com/2017/09/j-unit-ends-hepatitis-c-drug.html
0 Response to "J&J unit ends hepatitis C drug development in crowded market"
Post a Comment